NASDAQ:VIR Vir Biotechnology (VIR) Stock Price, News & Analysis → “The Stock Market’s Bull Run is Far from Over” -Barrons (From Vertical Research Advisory) (Ad) Free VIR Stock Alerts $10.13 +0.03 (+0.30%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$10.03▼$10.3450-Day Range$8.60▼$11.9052-Week Range$7.72▼$27.48Volume738,254 shsAverage Volume1.10 million shsMarket Capitalization$1.37 billionP/E RatioN/ADividend YieldN/APrice Target$34.38 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Vir Biotechnology alerts: Email Address Vir Biotechnology MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.57 Rating ScoreUpside/Downside239.3% Upside$34.38 Price TargetShort InterestBearish6.17% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.08Based on 4 Articles This WeekInsider TradingSelling Shares$808,066 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($4.04) to ($3.87) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.97 out of 5 starsMedical Sector635th out of 938 stocksBiological Products, Except Diagnostic Industry103rd out of 148 stocks 3.3 Analyst's Opinion Consensus RatingVir Biotechnology has received a consensus rating of Moderate Buy. The company's average rating score is 2.57, and is based on 4 buy ratings, 3 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $34.38, Vir Biotechnology has a forecasted upside of 239.3% from its current price of $10.13.Amount of Analyst CoverageVir Biotechnology has only been the subject of 2 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted6.17% of the float of Vir Biotechnology has been sold short.Short Interest Ratio / Days to CoverVir Biotechnology has a short interest ratio ("days to cover") of 5.Change versus previous monthShort interest in Vir Biotechnology has recently increased by 6.89%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldVir Biotechnology does not currently pay a dividend.Dividend GrowthVir Biotechnology does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for VIR. Previous Next 1.2 News and Social Media Coverage News SentimentVir Biotechnology has a news sentiment score of 0.08. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Vir Biotechnology this week, compared to 4 articles on an average week.Search InterestOnly 12 people have searched for VIR on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat FollowsOnly 4 people have added Vir Biotechnology to their MarketBeat watchlist in the last 30 days. This is a decrease of -20% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Vir Biotechnology insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $808,066.00 in company stock.Percentage Held by Insiders18.10% of the stock of Vir Biotechnology is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions65.32% of the stock of Vir Biotechnology is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Vir Biotechnology are expected to grow in the coming year, from ($4.04) to ($3.87) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Vir Biotechnology is -2.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Vir Biotechnology is -2.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVir Biotechnology has a P/B Ratio of 0.86. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Vertical Research Advisory“The Stock Market’s Bull Run is Far from Over” -BarronsBarron's reports that the "stock market's bull run is FAR from over…" And recent economic growth will fuel the price of select stocks in the coming months!Click here for all the details now… About Vir Biotechnology Stock (NASDAQ:VIR)Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It offers tobevibart + elebsiran for the treatment of chronic hepatitis delta; elebsiran + PEG-IFN-a, tobevibart ± elebsiran ± PEG-IFN-a, and elebsiran+ TLR8+PD-1 for the treatment of chronic hepatitis B; VIR-1388 and Cure mAb combination for the treatment of human immunodeficiency virus; VIR-8190 for the treatment of respiratory syncytial virus / human metapneumovirus; VIR-2981 for the treatment of influenza; VIR-1949 for the treatment of pre-cancerous HPV lesions; and VIR07229 and Sotrovimab for the treatment of COVID-19 infection under the Xevudy brand. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals SA. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies. The company was incorporated in 2016 and is headquartered in San Francisco, California.Read More VIR Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart VIR Stock News HeadlinesMarch 25, 2024 | americanbankingnews.comCritical Review: Vir Biotechnology (NASDAQ:VIR) versus Aura Biosciences (NASDAQ:AURA)March 21, 2024 | finance.yahoo.comBillionaire’s Biotech Bets: 3 Stocks Dominating Bill Gates’ PortfolioMarch 29, 2024 | Vertical Research Advisory (Ad)“The Stock Market’s Bull Run is Far from Over” -BarronsBarron's reports that the "stock market's bull run is FAR from over…" And recent economic growth will fuel the price of select stocks in the coming months!March 19, 2024 | investorplace.comFrom Six Figures to Seven: 3 Biotech Stocks Set to Make MillionairesMarch 19, 2024 | americanbankingnews.comHC Wainwright Reiterates "Buy" Rating for Vir Biotechnology (NASDAQ:VIR)March 16, 2024 | ca.finance.yahoo.comVIR Jul 2024 17.500 callMarch 15, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Vir Biotechnology (VIR) and IN8bio (INAB)March 15, 2024 | finance.yahoo.comVir Biotechnology, Inc. (VIR)March 29, 2024 | Vertical Research Advisory (Ad)“The Stock Market’s Bull Run is Far from Over” -BarronsBarron's reports that the "stock market's bull run is FAR from over…" And recent economic growth will fuel the price of select stocks in the coming months!March 11, 2024 | markets.businessinsider.comBuy Rating Affirmed for Vir Biotechnology on Promising HDV and HBV Programs and Strategic Market PositioningMarch 8, 2024 | markets.businessinsider.comMaintaining Buy Rating on ONCY Amidst Promising Clinical Advancements and Partnership PotentialMarch 5, 2024 | finance.yahoo.comVir Biotechnology Completes Enrollment of Phase 2 Chronic Hepatitis Delta SOLSTICE Trial Ahead of ScheduleFebruary 29, 2024 | finance.yahoo.comVIR Oct 2024 20.000 callFebruary 28, 2024 | seekingalpha.comVir Biotechnology: Making Progress In Hepatitis B And Hepatitis DeltaFebruary 26, 2024 | realmoney.thestreet.comThese 2 Biotech Stocks Are Rising Against the Recent Small-Caps DowntrendFebruary 26, 2024 | investorplace.com3 Highly Rated Biotech Stocks to Buy for 300% GainsFebruary 26, 2024 | markets.businessinsider.comOptimistic Outlook for Vir Biotechnology’s Clinical Programs and Financial Position Reinforces Buy RatingFebruary 25, 2024 | msn.comVir Biotechnology (VIR) Price Target Increased by 9.93% to 33.08February 23, 2024 | markets.businessinsider.comOptimistic Buy Rating on Vir Biotechnology Amidst Advancing HDV and HBV Programs and Upcoming Clinical CatalystsFebruary 23, 2024 | markets.businessinsider.comStrong Buy Rating for Vir Biotechnology on Promising Hepatitis Pipeline and Market Leadership PotentialFebruary 23, 2024 | finance.yahoo.comQ4 2023 Vir Biotechnology Inc Earnings CallFebruary 23, 2024 | marketwatch.comVir Biotechnology Shares Rise 14% on Terminated Collaboration with GSKFebruary 23, 2024 | finance.yahoo.comVir Biotechnology, Inc. (NASDAQ:VIR) Q4 2023 Earnings Call TranscriptFebruary 23, 2024 | businesswire.comVir Biotechnology to Participate in Upcoming Investor Healthcare ConferencesFebruary 22, 2024 | benzinga.comVir Biotechnology Stock (NASDAQ:VIR), Short Interest ReportFebruary 22, 2024 | finance.yahoo.comVir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial ResultsFebruary 22, 2024 | markets.businessinsider.comVir Biotechnology is about to announce its earnings — here's what Wall Street expectsSee More Headlines Receive VIR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vir Biotechnology and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/22/2024Today3/28/2024Next Earnings (Estimated)5/02/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:VIR CUSIPN/A CIK1706431 Webwww.vir.bio Phone415-906-4324FaxN/AEmployees587Year FoundedN/APrice Target and Rating Average Stock Price Target$34.38 High Stock Price Target$110.00 Low Stock Price Target$10.00 Potential Upside/Downside+239.3%Consensus RatingModerate Buy Rating Score (0-4)2.57 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($4.59) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-615,060,000.00 Net Margins-713.69% Pretax Margin-728.93% Return on Equity-34.92% Return on Assets-27.73% Debt Debt-to-Equity RatioN/A Current Ratio9.05 Quick Ratio9.05 Sales & Book Value Annual Sales$39.49 million Price / Sales34.63 Cash FlowN/A Price / Cash FlowN/A Book Value$11.82 per share Price / Book0.86Miscellaneous Outstanding Shares135,032,000Free Float110,591,000Market Cap$1.37 billion OptionableOptionable Beta0.42 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesDr. Ann M. Hanly Ph.D. (Age 53)Executive VP & Chief Technology Officer Comp: $842.23kDr. Phillip Pang M.D. (Age 48)Ph.D., Executive VP & Chief Medical Officer Comp: $837.38kDr. Marianne De Backer M.B.A. (Age 54)M.Sc., Ph.D., CEO & Director Dr. Klaus Frueh Ph.D. (Age 64)Co-Founder & Scientific Advisor Comp: $177.66kDr. Lawrence Corey M.D. (Age 76)Co-Founder & Scientific Advisor Dr. Louis J. Picker M.D.Co-Founder & Scientific AdvisorMr. Sung H. Lee (Age 54)Executive VP & CFO Dr. Jennifer Eileen Towne Ph.D.Executive VP & Chief Scientific OfficerMs. Heather Rowe ArmstrongVice President of Investor RelationsMs. Vanina De Verneuil J.D.Executive VP, General Counsel & Corporate SecretaryMore ExecutivesKey CompetitorsAutolus TherapeuticsNASDAQ:AUTLADMA BiologicsNASDAQ:ADMAAdaptimmune TherapeuticsNASDAQ:ADAPScholar RockNASDAQ:SRRKTarsus PharmaceuticalsNASDAQ:TARSView All CompetitorsInsiders & InstitutionsSung LeeSold 6,008 sharesTotal: $59,419.12 ($9.89/share)PNC Financial Services Group Inc.Bought 1,869 shares on 3/22/2024Ownership: 0.008%Vanguard Group Inc.Bought 1,096,473 shares on 3/11/2024Ownership: 9.107%George A ScangosSold 17,722 sharesTotal: $206,461.30 ($11.65/share)Ann M HanlySold 12,296 sharesTotal: $123,574.80 ($10.05/share)View All Insider TransactionsView All Institutional Transactions VIR Stock Analysis - Frequently Asked Questions Should I buy or sell Vir Biotechnology stock right now? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vir Biotechnology in the last year. There are currently 3 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" VIR shares. View VIR analyst ratings or view top-rated stocks. What is Vir Biotechnology's stock price target for 2024? 7 Wall Street analysts have issued 12-month price targets for Vir Biotechnology's shares. Their VIR share price targets range from $10.00 to $110.00. On average, they predict the company's share price to reach $34.38 in the next year. This suggests a possible upside of 239.3% from the stock's current price. View analysts price targets for VIR or view top-rated stocks among Wall Street analysts. How have VIR shares performed in 2024? Vir Biotechnology's stock was trading at $10.06 at the beginning of the year. Since then, VIR stock has increased by 0.7% and is now trading at $10.13. View the best growth stocks for 2024 here. When is Vir Biotechnology's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our VIR earnings forecast. How were Vir Biotechnology's earnings last quarter? Vir Biotechnology, Inc. (NASDAQ:VIR) posted its quarterly earnings results on Thursday, February, 22nd. The company reported ($0.86) earnings per share for the quarter, beating the consensus estimate of ($1.14) by $0.28. The company had revenue of $16.80 million for the quarter, compared to analysts' expectations of $11.18 million. Vir Biotechnology had a negative trailing twelve-month return on equity of 34.92% and a negative net margin of 713.69%. Vir Biotechnology's quarterly revenue was down 66.0% compared to the same quarter last year. During the same period last year, the business earned ($0.76) earnings per share. What ETFs hold Vir Biotechnology's stock? ETFs with the largest weight of Vir Biotechnology (NASDAQ:VIR) stock in their portfolio include iShares Genomics Immunology and Healthcare ETF (IDNA), Amplify Treatments, Testing and Advancements ETF (GERM), ALPS Medical Breakthroughs ETF (SBIO), Invesco S&P SmallCap Health Care ETF (PSCH), Invesco S&P SmallCap 600 Pure Growth ETF (RZG), Hartford Multifactor Small Cap ETF (ROSC) and First Trust Nasdaq Pharmaceuticals ETF (FTXH).SPDR S&P 600 Small Cap ETF (SLY). What is George Scangos' approval rating as Vir Biotechnology's CEO? 7 employees have rated Vir Biotechnology Chief Executive Officer George Scangos on Glassdoor.com. George Scangos has an approval rating of 85% among the company's employees. When did Vir Biotechnology IPO? Vir Biotechnology (VIR) raised $149 million in an initial public offering (IPO) on Friday, October 11th 2019. The company issued 7,100,000 shares at $20.00-$22.00 per share. Goldman Sachs, J.P. Morgan, Cowen and Barclays served as the underwriters for the IPO. Who are Vir Biotechnology's major shareholders? Vir Biotechnology's stock is owned by many different institutional and retail investors. Top institutional investors include Vanguard Group Inc. (9.14%), Vanguard Group Inc. (9.11%), Baillie Gifford & Co. (2.95%), Bridgeway Capital Management LLC (1.00%), Northern Trust Corp (0.70%) and Charles Schwab Investment Management Inc. (0.56%). Insiders that own company stock include Ann M Hanly, Charles Elliott Sigal, Endurance (Cayman) Ltd Svf, George A Scangos, Herbert Virgin, Howard Horn, Janet Napolitano, Johanna Friedl-Naderer, Medpace Investors, Llc, Phillip Pang, Robert J More, Robert J More, Saira Ramasastry, Steven J Rice, Sung Lee, Vicki L Sato and Vicki L Sato. View institutional ownership trends. How do I buy shares of Vir Biotechnology? Shares of VIR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:VIR) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeGrab Your Free Bitcoin Today!Crypto Swap ProfitsMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceTop Project Outperforms BTC in 2023…Crypto 101 Media“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyFed launches fourth dollar overhaulStansberry ResearchAI healthcare stock poised for 36,996% growth?Behind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vir Biotechnology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.